• Home
  • Study Details
COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

Metastatic Triple Negative Breast Cancer Study

We are studying how well a new medicine called Sacituzumab Tirumotecan works by itself and when combined with another medicine called pembrolizumab. We are comparing these treatments to the usual chemotherapy to see which one is better and safer for people with a specific type of breast cancer that has come back or spread and can't be removed by surgery.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Julia Rauch
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

25-0557

ClinicalTrials.gov

NCT06841354

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research